Multiple Myeloma

Criteria to qualify for this study: Drug used in study:
  • Relapsed/Refractory to prior Revlimid treatment.

MM 66 CA204142 Bristol-Myers Squibb

A Phase 2 multiple cohort study of Elotuzumab in combination with Pomalidomide and low dose Dexamethasone (EPd), and in combination with Nivolumab (EN) in patients with MM relapsed or refractory to prior treatment with Lenalidomide.

Criteria to qualify for this study: Drug used in study:
  • Must have had transplant due to high-risk features / Engraftment of neutrophils ANC greater than 1000 / Engraftment of platelets, PLT greater than 60 / Achievement of at least a PR prior to transplant / Absence of GI symptoms / Cord blood or haplo transplant not allowed

MM 42 SCRI Millennium

Open-Label Study to Determine the Feasibility of MLN9708 as Maintenance after Allogeneic Stem Cell Transplant for Multiple Myeloma, Followed by an Expansion Phase at the Maximum-Tolerated Dose (MTD)

Criteria to qualify for study: Drug used in study:
  • New Diagnosed

MM 61 SCRI BMS CA204-154

A Phase 2 study to Assess the Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide and Dexamethasone (Erd) in the Induction, Consolidation and Maintenance Treatment of Transplant-Eligible Patients Newly Diagnosed with MM.

Criteria to qualify for study: Drug used in study:
  • Relapsed Refractory

MM 75 CA209602 Bristol-Myers Squibb

An Open-Label Randomized Phase 3 Trial of Combinations of Nivolumab, Elotuzumab, Pomalidomide and Dexamethasone in Relapsed and Refractory MM.

ON HOLD

Criteria to qualify for study: Drug used in study:
  • Relapsed Refractory

MM 78 Celgene CC-4047-MM-014

A Phase 2, Multicenter, Multi-Cohort, Open-Label Study of Pomalidomide in Combination with Low-Dose Dexamethasone or Pomalidomide in Comination with Low-Dose Dexamethasone and Dartumumab in Subjects with Relapsed or Refractory Multiple Myeloma Following Lenadliomide-Based Therapy in the First or Second line Setting.

Criteria to qualify for study: Drug used in study:
  • Relapsed Refractory

MM 76 Celgene MED14736-MM-003

A Phase 2, Multicenter, Open-Label, Study to Determine the Safety and Efficacy for the Combination of Durvalumab (Durva) and Daratumumab (Dara) (D2) in Subjects with Relapsed and Refractory Multiple Myeloma.

ON HOLD

Criteria to qualify for this study: Drug used in study:
  • R/R, AML/MM/DLBCL

HEMREF 51 Medimmune

A Phase 1 Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Antitumor Activity of MEDI7247 in Patients with Selected Relapsed/Refractory Hematological Malignancy "ECOG 0-1, Liver Function Tests: AST and ALT ? 3 × ULN; ? 5 × the ULN for either value if due to leukemia or lymphoma involvement, and serum TBL ? 1.5 × ULN, unless consistent with Gilbert’s syndrome (ratio between total and direct bilirubin > 5), for which TBL ? 2.5 × ULN is allowed. AML - Hydroxyurea, if clinically indicated, is permitted but must be stopped 24 hours prior to the first scheduled dose of MEDI7247 MM-May have received approved agents or radiation within 14 days OR immunotherapy within 28 days of the first scheduled dose of MEDI7247"

Newly Diagnosed

Criteria to qualify for this study: Drug used in study:
  • Must have at least 10% plasma cells in the marrow M-protein must be present in the serum and/or urine
  • Must have at least 1 myeloma-related organ dysfunction per CRAB criteria
  • Cannot have amyloid
  • PLT must be at least 50 unless marrow contains >50% plasma cells - then PLT must be at least 30
  • ANC must be at least 1000

Dana Farber DFCI 10-106

A Randomized Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib and Dexamethasone (RVD) to High-Dose Treatment with Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients up to 65 Years of Age